Our company Gen İlaç ve Sağlık Ürünleri San. ve Tic. A.Ş. (GEN) is pleased to share with the public our efforts to develop an innovative research drug in line with our growth, globalisation and innovation strategies:
GN-037 topical cream, developed in our GEN R&D laboratories and our company’s innovative research drug in the clinical research development phase, was shown to be safe and effective in a Phase 1 study in healthy volunteers and patients with psoriasis. The scientific article containing the results of this study was published in the journal “Dermatology and Therapy“- an important and respected international journal in the field of dermatology.
As we have previously shared with the public, in the next phase of clinical development studies, patient recruitment continues in 18 centres in our country in a Phase 2 clinical study titled “A multicenter, randomised, double-blind, placebo-controlled, parallel-group Phase 2 study evaluating the clinical efficacy and safety of GN-037 cream used in the treatment of mild to moderate plaque psoriasis”. Patient recruitment in this Phase 2 study, planned to include 190 patients, is expected to be completed by the end of 2023.
Psoriasis is a recurrent, chronic skin disease that can occur in various clinical forms at any age. The prevalence of psoriasis varies in different societies and geographical regions. It is reported that the majority of psoriasis is 1.5-2% in the general population. 70-80% of patients with psoriasis have limited/localised disease, managed with topical treatment only. In this respect, topical treatment is the most common form of psoriasis management. According to available information, it is estimated that there are approximately 1,300,000 psoriasis patients in our country, and about 900,000 of these patients are treated with topical medications.
It was respectfully announced to the public.
